Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
225 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (7)

Medical Condition

  • Show all (1219)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (18)
    • (-) Amyloidosis (2)
    • Anemia (1)
    • Sickle Cell Disease (4)
  • Bone & Muscle (10)
  • Cancer (101)
  • Child Development (4)
  • COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (12)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (26)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (187)
  • Heart Disease (130)
  • Infectious Disease (48)
  • Insomnia (3)
  • Kidney Disease (12)
  • Liver Disease (52)
    • Cirrhosis of the Liver (5)
    • Hepatic Encephalopathy (2)
    • Hepatitis (10)
    • Liver Failure (2)
    • (-) NASH (3)
  • Lung Disease (31)
  • Meniere's Disease (1)
  • Neurological Disorders (126)
  • Nutrition (5)
  • Obesity (9)
  • Obstetrics & Gynecology (55)
    • Abdominal Cramping (1)
    • Contraception (15)
    • Fertility (2)
    • Preeclampsia (1)
    • Pregnancy (18)
    • Prenatal Abnormalities (1)
    • (-) Reproductive & Hormonal Disorders (2)
  • Pain Management (1)
  • Pediatrics (98)
  • Psychiatric Disorders (67)
  • Rehabilitation (9)
  • Stroke (7)
  • Surgery (7)
  • Transplant (45)
  • Urology (3)
  • Vascular Conditions (10)
Displaying 1 - 7 of 7

Study of Rapamycin in Delaying the Start of Menopause

Condition: Obstetrics & Gynecology / Reproductive & Hormonal Disorders
Investigator: S. Zev Williams, MD, PhD
Status: Closed
Researchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation.
Read More

Study of ION-682884 (SC) in patients with TTR Amyloidosis Polyneuropathy

Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Read More

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Read More

Study of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

Condition: Liver Disease / NASH
Investigator: Julia Wattacheril, MD, MPH
Status: Closed
The Sponsor is conducting this study to find out how safe and effective the investigational drug (alsocalled a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH. Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several…
Read More

TARGET-NASH: Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. The main purpose of this research study is to collect and study information on patients with NAFLD/NASH.The goal of this study is to observe any treatment…
Read More

Study of Emricasan in subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and efficacy of a drug called Emricasan (IDN-6556) in reducing the risk…
Read More

A study for Menopausal women using an investigational drug TX004-HR to reduce the frequency of hot flushes.

Condition: Obstetrics & Gynecology / Reproductive & Hormonal Disorders
Investigator: Rogerio Lobo, MD, FACOG
Status: Closed
The purpose of this study is to evaluate a new experimental (investigational) oral combination hormone drug product containing estradiol (a form of the estrogen) and progesterone (a female hormone that regulates the inner lining of the uterus called the endometrium) for postmenopausal women who have hot flushes. The estradiol and progesterone used in this…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science